Advanced vaccines for a healthier future
The story began back in 1956: At that time the founders of Immuno in Austria, Dr. Eibl and Dr. Schwarz, successfully cooperated in the development of a polio vaccine. And twenty years later, in 1976, Immuno started production of the vaccine against tick-borne encephalitis (TBE).
The other story began in 1990: North American Vaccines was founded. And in 1998, this company was the first independent vaccine manufacturer in more than a decade to enter the US pediatric vaccines market with its first product, a diphteria, tetanus, acellular pertussis (DTaP) vaccine. Only two years later a group C meningococcal conjugate vaccine , was launched in the UK.
Today, we are all a part of Baxter Vaccines and we are part of US-based Baxter Healthcare Corporation. At Baxter Vaccines, we are on our way to be a leading force in the vaccines market driven by the promises of a healthier future.
- Baxter's TBE vaccine, is today licensed in all countries where this disease is endemic and it is helping to reduce the morbidity and mortality of this potentially life-threatening disease. In Austria, previously one of the most severely affected countries, an extensive public health effort has contributed effectively to reaching an overall vaccination rate of 84%, with a corresponding decrease in the number of hospitalized cases of TBE.
- Baxter's group C meningococcal conjugate vaccine has been used to protect millions of people since its introduction. It utilizes a meningococcal antigen fused to a carrier protein previously used in the Hib conjugate vaccine. It is the first meningococcal vaccine with a 2-dose basic immunization licensed for infants from two to twelve months of age. The vaccine induces an excellent antibody response and long-term immunological memory in all age groups from infants to adults.
- Baxter’s influenza vaccine, currently in the late stage development, will be the first in the industry to be based on the Vero cell continuous cell line. It is completely free from egg proteins, which minimizes the risk of allergic reactions, exposure to antibiotics, and free of the preservative thiomersal. Today, this economic technology of influenza vaccine production represents the most modern and reliable way to maintain high quality standards of the product and to ensure sufficient quantities of vaccines in emergency situations.
- Baxter is currently able to supply ACAM2000 - the new, second-generation smallpox vaccine, under IND application from the US FDA.